Fry Laboratories — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Fry Laboratories is a private, Arizona-based diagnostics company that historically provided specialized testing services for complex conditions like Lyme disease and chronic inflammatory illnesses. Its core technology platform, RIDI™ (Rapid Infectious Disease Identification by Sequencing), uses next-generation DNA sequencing to detect bacteria, fungi, and protists. The company is currently in a transitional state, having halted routine clinical services to focus on R&D and potential partnerships for its sequencing-based diagnostic and antibiotic resistance detection technologies. Leadership includes founder Dr. Stephen E. Fry and CEO Judith Joseph.

Infectious DiseasesAutoimmune DiseasesVector-Borne Diseases

Technology Platform

RIDI™ (Rapid Infectious Disease Identification by Sequencing) - a next-generation DNA sequencing platform for detection and identification of bacteria, fungi, and protists, combined with proprietary software, chemistry, and semi-quantitative microscopy.

Opportunities

The growing need for precise diagnostics in complex chronic illnesses like Lyme disease and the global crisis of antimicrobial resistance (AMR) present significant opportunities.

The company's sequencing platform could address the unmet need for direct, unbiased pathogen detection and resistance profiling, positioning it for partnerships in the expanding clinical metagenomics market.

Risk Factors

The suspension of all clinical services eliminates its primary revenue stream, creating severe financial and operational risk during its R&D pivot.

The company faces intense competition in the NGS diagnostics space from larger, well-funded entities and must successfully secure partnership or investment funding to survive and advance its technology.

Competitive Landscape

Fry Labs competes in the niche but competitive field of advanced infectious disease diagnostics, particularly for Lyme and chronic complex illnesses. Key competitors include large reference labs (Quest, LabCorp), specialized Lyme testing labs, and companies commercializing clinical metagenomic NGS (e.g., Karius). Its success depends on demonstrating superior accuracy or unique capabilities with its proprietary platform.

More companies in Diagnostics & Precision Medicine →More companies in United States →